{"disease":{"id":"squamous-cell-cancer-of-head-and-neck-scchn","name":"squamous cell cancer of head and neck scchn"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07125755","title":"Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":386,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07259915","title":"Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":152,"lead_sponsor_name":"Centre Henri Becquerel","has_results":false},{"nct_id":"NCT04844073","title":"A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":95,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05070247","title":"A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":61,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT07348887","title":"Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT07405645","title":"Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Virginia","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}